Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet‐activating factor is mediated by leukotriene C4
Open Access
- 19 July 1986
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 88 (3) , 595-605
- https://doi.org/10.1111/j.1476-5381.1986.tb10240.x
Abstract
1 Platelet-activating factor (Paf, 0.04-4.50 nmol) dose-dependently induced coronary vasoconstriction and decreased cardiac contractility in rat, isolated perfused hearts and concomitantly released leukotriene-like bioactivity into the cardiac effluent. 2 Platelet-activating factor (0.9 nmol) induced an increase in 6-keto-prostaglandin F1α (6-keto-PGF1α), PGF2α, PGE2 and thromboxane B2 (TXB2) measured by radioimmunoassay (RIA) of cardiac effluents following partial purification using C18 Sep-Paks. 3 The leukotriene-like bioactivity released by Paf was identified as leukotriene C4 (LTC4) using a combination of isolation on reverse phase-h.p.l.c. (r.p.h.p.l.c.) and quantitation by RIA. In addition, LTB4 was also identified by r.p.h.p.l.c. and the levels, determined by RIA, were within the range having biological activity. 4 The release of cyclo-oxygenase products by Paf was prevented by indomethacin (2.8 μM), markedly attenuated by diethylcarbamazine (7.7 mM) but unaffected by FPL 55712 (1.9 μM)-pretreatment. Furthermore, LTC4 (50 pmol) did not increase the release of the cyclo-oxygenase products measured. 5 The release of LTB4 and LTC4 appeared to be unaffected by indomethacin pretreatment whereas diethylcarbamazine-pretreatment markedly inhibited release. 6 The coronary vasoconstriction induced by Paf (0.9 nmol) was attenuated by pretreatment with indomethacin or diethylcarbamazine, whereas FPL 55712 caused a marked inhibition of the response. In contrast, the decrease in cardiac contractility was prevented by indomethacin or diethylcarbamazine and unaffected by FPL 55712 pretreatment. 7 It is concluded that LTC4 may be largely responsible for the coronary vasoconstriction induced by Paf with cyclo-oxygenase products having a possible modulatory role whereas the latter appear to be involved in the Paf-induced decrease in cardiac contractility.This publication has 40 references indexed in Scilit:
- Platelet-activating factor stimulation of peptidoleukotriene release: Inhibition by vasoactive polypeptideBiochemical and Biophysical Research Communications, 1984
- Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs.Journal of Clinical Investigation, 1984
- Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea-pig heartsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.Journal of Clinical Investigation, 1983
- Nonimmunological Production pf Leukotrienes Induced by Platelet-Activating FactorScience, 1982
- The effect of lipoxygenase inhibitors and diethylcarbamazine on the immunological release of slow reacting substance of anaphylaxis (SRS-A) from guinea-pig chopped lungJournal of Pharmacy and Pharmacology, 1981
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980
- Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heartNature, 1977
- Degradation of porstaglandin F2alpha in the human pulmonary circulation.Thorax, 1976